Skip to main content

Bayer defies critics with $62 billion Monsanto offer

















Business | Mon May 23, 2016 8:01am EDT
Related: DEALS

FRANKFURT | BY LUDWIG BURGER AND GEORGINA PRODHAN











The corporate logo of Bayer is seen at the headquarters building in Caracas March 1, 2016. Picture taken March 1, 2016.
REUTERS/MARCO BELLO/FILE PHOTO
 







German drugs and crop chemicals group Bayer has offered to buy U.S. seeds company Monsanto for $62 billion in cash, defying criticism from some of its own shareholders in a bid to grab the top spot in a fast-consolidating farm supplies industry.



The unsolicited proposal, which includes debt, would be the largest foreign takeover by a German company if accepted.



The move, which would eclipse a planned combination of Dow Chemical and DuPont's agriculture units, comes just three weeks after Werner Baumann took over as Bayer CEO, and was condemned by a major shareholder as "arrogant empire-building" when news of the proposal emerged last week.



Giving details for the first time, Bayer said on Monday it would offer $122 per share, a 37 percent premium to Monsanto's stock price before rumors of a bid surfaced.




"We fully expect a positive answer of the Monsanto board of directors," Baumann told reporters on a conference call, describing criticism from some investors as "an uneducated reaction in the media" when deal terms were not yet known, and driven by an element of surprise.




Monsanto, which said last week it had a received an approach from Bayer but gave no details, has yet to comment on the offer. The U.S. company's shares jumped 9.5 percent to $111.17 in pre-market trading.










"UPPER LIMIT"





Global agrochemicals companies are racing to consolidate, partly in response to a drop in commodity prices that has hit farm incomes and also due to the growing convergence between seeds and pesticides markets.







ChemChina is buying Switzerland's Syngenta for $43 billion after Syngenta rejected a bid from Monsanto, while Dow and DuPont are forging a $130 billion business.




With German rival BASF also looking into a possible tie-up with Monsanto, Bayer has moved to avoid being left behind.




Baumann rejected suggestions from some investors that Bayer should instead try to forge a joint venture with Monsanto, saying this would have tax disadvantages.



Sources close to the matter have said BASF is unlikely to start a bidding war with Bayer. BASF declined to comment on Monday. But analysts say Bayer might still have to pay more to persuade Monsanto and its shareholders to sell up.



That could be a problem, with some saying Bayer's proposal, at 15.8 times its earnings before interest, tax, depreciation and amortization for the year ended Feb. 29, is already a stretch for the German company.



"The price that has now been disclosed is at the upper limit and it is just about economical. Should it rise further, which is to be assumed, the takeover will become increasingly unattractive," said Markus Manns, a fund manager at Union Investment, Bayer's 14th biggest investor.



Shares in Bayer, which had already fallen 14 percent since rumors of a bid emerged last week, dropped as much as 3.6 percent on Monday to a new 2-1/2 year low of 86.3 euros.







"VERY AMBITIOUS"



Bayer said it would finance the bid with a combination of debt and equity, primarily a share sale to existing investors. Equity would account for about a quarter of the deal value.



Equinet analyst Marietta Miemietz, who has a 'buy' rating on Bayer stock, said the extra debt appeared manageable but could limit Bayer's ability to invest in its healthcare business, which some analysts think needs a boost to its drugs pipeline.




Baumann said Bayer would continue to develop its healthcare arm, which includes stroke prevention pill Xarelto and aspirin, the painkiller it invented more than a century ago.




"We are not feeding Peter by starving Paul here," he said, adding no asset sales were planned to help pay for the deal.



Bayer also forecast synergies from a deal with Monsanto would boost annual earnings by around $1.5 billion after three years, plus additional future benefits from integrated product offerings - a reference to its push to combine the development and sale of seeds and crop protection chemicals.





Berenberg analysts, who have a 'buy' rating on Bayer shares, described the synergies estimate as "very ambitious".







(Reporting by Maria Sheahan, Ludwig Burger and Patricia Weiss; Writing by Ludwig Burger and Georgina Prodhan; Editing by Edwina Gibbs and Mark Potter)





http://www.reuters.com/article/us-monsanto-m-a-bayer-idUSKCN0YE0DZ




Popular posts from this blog

MEET MELANIA TRUMP: The 5'11" supermodel married to Donald Trump

Aly Weisman, INSIDER

Sep. 2, 2015, 3:28 PM 










Chip Somodevilla/Getty Images







While Donald Trump loves to be the center of media attention, his third and current wife, Melania Trump, is a bit more camera shy.










The Slovenian-born model keeps a lower profile than her husband, doing philanthropy work, raising their son, working on a jewelry collection with QVC, and creating a $150-an-ounce caviar moisturizer.



With Trump on the campaign trail, Melania has stoically stood by his side.



But who exactly is Melania and where did she come from? Learn about Trump's other half here ...




Melania Knauss was born April 26, 1970, in Slovenia.



Wikimedia/Getty







The 5'11" brunette began her modeling career at 16, and signed with a modeling agency in Milan at 18.


Chris Hondros/Newsmakers via Getty









She took a break from modeling to get her degree in design and architecture at the University of Ljubljana in Slovenia.







Wikimedia/Getty

Source: MelaniaTrump.com









But after graduating, her modeling career took off and Me…

THE MOST SOUGHT AFTER MANGOES IN THE WORLD ....

While "Flavor" is very subjective, and each country that grows mangoes is very nationalistic, these are the mango varieties that are the most sought after around the world because of sweetnesss (Brix) and demand.

The Chaunsa has a Brix rating in the 22 degree level which is unheard of!
Carabao claims to be the sweetest mango in the world and was able to register this in the Guiness book of world records.
Perhaps it is time for a GLOBAL taste test ???





In alphabetical order by Country....










India




Alphonso




Alphonso (mango)
From Wikipedia, the free encyclopedia







Alphonso (हापुस Haapoos in Marathi, હાફુસ in Gujarati, ಆಪೂಸ್ Aapoos in Kannada) is a mango cultivar that is considered by many[who?] to be one of the best in terms of sweetness, richness and flavor. 


It has considerable shelf life of a week after it is ripe making it exportable. 

It is also one of the most expensive kinds of mango and is grown mainly in Kokan region of western India.

 It is in season April through May and the fruit wei…

7 Medicinal Properties Of Mango Leaves That You Aren’t Aware Of!

By admin

• On December 11, 2016 • 



Many of us know how delicious mangoes are!




Basically, mangoes are very nutritious and healthy to eat regularly, where not only just kids but also adults love to eat. These mangoes are only found in the large areas of India and it is said to be the hub of mangoes where huge quantities of mangoes are exported from this country to all the countries.


When we look into mango leaves­ they’re basically like the all other leaves i.e. green in color.
 At first they’re reddish in color and as they grow­ they turn into dark greenish color.

Mango leaves are rich in:
Vitamin A
Vitamin B
Vitamin C
Also rich in flavonoids and phenols
Have powerful antioxidant properties



These were just the qualities of these leaves­ now we’ll understand about the importance of these leaves and the medical impact on the human body.


1. Diabetes


These leaves are rich in tannins called anthocyanidins­ useful for treating diabetes in the early stage.
The method of using these leaves is simple­ first w…